2020-2027 Analysis and Review Neonatal Apnea Treatment Market

Neonatal Apnea Treatment Market

Neonatal Apnea Treatment Market by Drug Class (Aminophylline, Doxapram and Caffeine Citrate), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020 – 2027

29-07-2020 REP-HC-5147 40 Tables 110 pages Format

The neonatal apnea treatment market was valued at USD 232.7 Mn by 2019. The growing incidence of neonatal apnea in preterm birth babies worldwide primarily drives the market growth. Additionally, the effective implementation of treatment guidelines pertaining to the management and care of neonatal intensive units across the globe further accentuates the market growth.

Neonatal Apnea Treatment Market

Neonatal apnea treatment is a major concern for pediatric surgeons engaged in the provision of neonatal intensive care. Bradycardia in the neonates is considered as clinically significant if the heartbeat slows by 30 bpm from the resting heart rate. Secondly, the oxygen saturation level below 85% is considered pathologic in the neonates if this condition persists for more than 5 seconds.

The major segments related to the neonatal apnea treatment market are: 

By Drug Class (2017–2027; US$ Mn)

Aminophylline

Theophylline

Caffeine Citrate

By Distribution Channel (2017–2027; US$ Mn)

Hospital Pharmacy

Retail Pharmacy

Others

Geography Segment (2017–2027; US$ Mn)

North America

U.S.
Canada

Europe

United Kingdom
Germany
Russia
France
Italy
Spain
Ukraine
Rest of Europe

Asia Pacific

China
Japan
Rest of Asia Pacific

Latin America (LATAM)

Brazil
Mexico
Rest of Latin America

Middle East and Africa (MEA)

GCC
Rest of MEA 

Justification for study?

  • The intention of the study is to give a comprehensive outlook of the global neonatal apnea treatment market
  • The overall segmentation of the neonatal apnea treatment market, by drug class, distribution channel, and geography is minutely studied. Aminophylline and hospital pharmacy are dominating the drug class and distribution channel segments respectively
  • Growing incidence of neonatal apnea worldwide
  • Effective implementation of treatment guidelines pertaining to neonatal intensive care across the globe

Report gist?

  • The study of the global neonatal apnea treatment market includes qualitative analysis of factors such as drivers, restraints, and opportunities
  • The report covers the qualitative and quantitative analysis of the overall market segmented on the basis of drug class and distribution channel and categorization of the same at the geography level
  • This research report presents the analysis of each segment from 2017 to 2027 in which 2019 is considered as the base year. The compounded annual growth rate is calculated for the respective segments from 2020 to 2027

The study includes the profiles of major market players with a significant global and regional presence along with top company positioning. 

Significant customers?

  • This study is suitable for industry participants and stakeholders in the pharmaceutical manufacturers actively engaged in the production and marketing of drugs widely employed in the management of neonatal apnea
  • The report will benefit pediatric surgeons actively engaged in providing neonatal intensive care worldwide
  • Managers with financial institutions looking to publish recent and forecasted statistics pertaining to neonatal apnea treatment market
  • Financial institutions, venture capitalist, analysts, investors, government organizations, policymakers, regulatory authorities, researchers, looking for insights into the market to determine future strategies 

Segment Analysis

Caffeine citrate is spearheading the drug class segment for the neonatal apnea treatment market. It is widely employed by pediatric surgeons worldwide for the successful extubation in preterm births. Caffeine has a wider therapeutic index among all the methylxanthines drugs, hence the occurrence of a drug overdose is less likely to occur. The only limitation associated with caffeine is that it might reduce the rate of bronchopulmonary dysplasia in neonates having very low birth weights. Aminophylline is considered as the alternative methylxanthine for the treatment of neonatal apnea owing to its ability to improve the contraction of thoracic musculature in neonates who are at risk of suffering from bronchopulmonary dysplasia. The negative aspect associated with aminophylline is that it might decrease the cerebral blood flow and several clinical trial investigations have suggested the possible role of aminophylline in worsening the necrotizing enterocolitis.

Hospital pharmacy is presently leading the distribution channel for the neonatal apnea treatment market. Severe drug-related adverse events associated with methylxanthines drugs such as restlessness, nervousness, loss of appetite, etc, make it mandatory for the accurate drug dispensing of methyxanthines drugs under the supervision of hospital pharmacist. Retail pharmacy is expected to register rampant market growth in the near future on account of the constant rise in the generic drugs market in the developing regions and its ability to provide medical aid to patients residing in remote locations.

North America is representing the largest market share in the geography segment for the neonatal apnea treatment market. The growing incidence of neonatal apnea primarily drives market growth in the region. As per the latest research citings provided by the American Academy of Pediatrics (AAP), approximately 70% of the babies born before 34 weeks of gestation suffer from neonatal apnea. Furthermore, the affordable reimbursement scenario associated with the use of methyxanthines in managing neonatal apnea and domicile of major players such as Pfizer, Inc., Omega Laboratories Ltd., Mylan Pharmaceutical Industries Limited. Together accentuate the market growth in the region. Europe is considered as the second-largest regional segment for neonatal apnea treatment market owing to the nurturing regulatory environment provided by the European Medical Agency (EMA) for the sale and distribution of methyxanthines drugs for the treatment of neonatal apnea prevalent in the region. The Asia Pacific is anticipated to be the fastest-growing regional segment for neonatal apnea treatment market on account of the effective implementation of the treatment guidelines pertaining to the management of neonatal intensive care and flourishing generic drugs market.

Select License Type

$4,600
$6,600
$13,200

Safe and Secure SSL Encrypted

Have a Question?

We will help you find what you are looking for.

Call 1-518-730-1560

Contact sales

How can we help you?

Get in touch with us or find an office closest to you.